CURATIS N AG (CURN) - Total Liabilities
Based on the latest financial reports, CURATIS N AG (CURN) has total liabilities worth CHF9.96 Million CHF (≈ $12.59 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
CURATIS N AG - Total Liabilities Trend (2002–2024)
This chart illustrates how CURATIS N AG's total liabilities have evolved over time, based on quarterly financial data. See CURN current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
CURATIS N AG Competitors by Total Liabilities
The table below lists competitors of CURATIS N AG ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BIOCELTIX S.A. ZY -10
F:XI3
|
Germany | €2.36 Million |
|
Frontier Lithium Inc
V:FL
|
Canada | CA$35.93 Million |
|
Sarla Performance Fibers Limited
NSE:SARLAPOLY
|
India | Rs3.16 Billion |
|
Kino Indonesia Tbk PT
JK:KINO
|
Indonesia | Rp2.81 Trillion |
|
Big River Industries Ltd
AU:BRI
|
Australia | AU$145.90 Million |
|
Woorim Machinery Co. Ltd
KQ:101170
|
Korea | ₩17.19 Billion |
|
SYNergy ScienTech Corp
TW:6558
|
Taiwan | NT$393.72 Million |
|
Garuda Indonesia Persero Tbk
JK:GIAA
|
Indonesia | Rp138.13 Trillion |
Liability Composition Analysis (2002–2024)
This chart breaks down CURATIS N AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CURN market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.50 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.62 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CURATIS N AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CURATIS N AG (2002–2024)
The table below shows the annual total liabilities of CURATIS N AG from 2002 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CHF9.94 Million ≈ $12.56 Million |
+2200.46% |
| 2023-12-31 | CHF432.00K ≈ $546.16K |
-94.08% |
| 2022-12-31 | CHF7.29 Million ≈ $9.22 Million |
+1260.63% |
| 2021-12-31 | CHF536.00K ≈ $677.65K |
+39.58% |
| 2020-12-31 | CHF384.00K ≈ $485.48K |
-85.91% |
| 2019-12-31 | CHF2.73 Million ≈ $3.45 Million |
+50.36% |
| 2018-12-31 | CHF1.81 Million ≈ $2.29 Million |
-9.62% |
| 2017-12-31 | CHF2.01 Million ≈ $2.54 Million |
-2.05% |
| 2016-12-31 | CHF2.05 Million ≈ $2.59 Million |
+18.66% |
| 2015-12-31 | CHF1.73 Million ≈ $2.18 Million |
-15.93% |
| 2014-12-31 | CHF2.05 Million ≈ $2.60 Million |
-30.78% |
| 2013-12-31 | CHF2.97 Million ≈ $3.75 Million |
-61.06% |
| 2012-12-31 | CHF7.62 Million ≈ $9.63 Million |
+48.95% |
| 2011-12-31 | CHF5.11 Million ≈ $6.46 Million |
-19.88% |
| 2010-12-31 | CHF6.38 Million ≈ $8.07 Million |
+167.14% |
| 2009-12-31 | CHF2.39 Million ≈ $3.02 Million |
-30.73% |
| 2008-12-31 | CHF3.45 Million ≈ $4.36 Million |
-62.24% |
| 2007-12-31 | CHF9.13 Million ≈ $11.55 Million |
+98.16% |
| 2006-12-31 | CHF4.61 Million ≈ $5.83 Million |
-64.49% |
| 2005-12-31 | CHF12.98 Million ≈ $16.42 Million |
-42.10% |
| 2004-12-31 | CHF22.42 Million ≈ $28.35 Million |
+4.30% |
| 2003-12-31 | CHF21.50 Million ≈ $27.18 Million |
+56.82% |
| 2002-12-31 | CHF13.71 Million ≈ $17.33 Million |
-- |
About CURATIS N AG
Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases. It offers its products in the areas of fentanyl, breakthrough pain, antiplatelet, metastatic hormone receptor-positive breast cancer, anti-arrhythmic, nasal oil, wilson's disease, cyanide poisoning, digoxin toxicity, antih… Read more